Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920266'
s EV-to-FCF Range Over the Past 10 Years
Min: -25.05 Med: 10.78 Max: 1249.07
Current: -15.59
During the past 13 years, the highest EV-to-FCF of Yunnan Biovalley Pharmaceutical Co was 1249.07. The lowest was -25.05. And the median was 10.78.
BJSE:920266's EV-to-FCF is ranked worse than 100% of 561
companies
in the Drug Manufacturers industry
Industry Median: 21.29
vs BJSE:920266: -15.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Yunnan Biovalley Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Yunnan Biovalley Pharmaceutical Co's share price for today is ¥7.57.
Yunnan Biovalley Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Yunnan Biovalley Pharmaceutical Co EV-to-FCF Related Terms
Yunnan Biovalley Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yunnan Biovalley Pharmaceutical Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Yunnan Biovalley Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yunnan Biovalley Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yunnan Biovalley Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Yunnan Biovalley Pharmaceutical Co's EV-to-FCF falls into.
Yunnan Biovalley Pharmaceutical Co's current Enterprise Value is ¥864.6 Mil.
Yunnan Biovalley Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-55.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) has a EV-to-FCF of -15.59 as of Aug. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. According to the industry distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #999999 out of 561 companies in the Drug Manufacturers industry.
Is Yunnan Biovalley Pharmaceutical Co's EV-to-FCF too high?
Yunnan Biovalley Pharmaceutical Co's current EV-to-FCF is -15.59. Based on the distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #999999 out of 561 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Yunnan Biovalley Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Yunnan Biovalley Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Yunnan Biovalley Pharmaceutical Co ranks #999999 out of 561 companies for EV-to-FCF. This places Yunnan Biovalley Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 21.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.29, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yunnan Biovalley Pharmaceutical Co's current EV-to-FCF is -15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yunnan Biovalley Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co (BJSE:920266) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.81, compared to a current price of ¥7.57 — trading 3.1% below its estimated fair value. The current EV-to-FCF is -15.59. Yunnan Biovalley Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Yunnan Biovalley Pharmaceutical Co (BJSE:920266), the current EV-to-FCF is -15.59 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Overvalued in 2026?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.57 is trading 3.1% below its estimated GF Value™ of ¥7.81.
GuruFocus considers Yunnan Biovalley Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920266:
EV-to-FCF: -15.59
GF Value™: ¥7.81 vs. price of ¥7.57 (3.1% below fair value)
No single metric tells the full story. See the BJSE:920266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.
74GF Score
Get the complete analysis for BJSE:920266
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920266 has been successfully added to your 
